janus kinase (JAK) inhibitor - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 hospitalized
	COVID-19 severe or critically
janus kinase (JAK) inhibitor
baricitinib	Tziolos COV-BARRIER ...
ruxolitinib	Cao DEVENT
TD-0903
TD-0903 10mg	Singh ...
TD-0903 1mg	Singh ...
TD-0903 3mg	Singh ...

1 studies excluded by filtering options 2

6415

Cantini, 2020

2

31

0

excluded

not a RCT

risk of bias not avaialble